Cetirizine Dihydrochloride — Drug Intelligence | 12 EU Trials

Filter these 12 trials by condition, phase, country and more.

Open in Search →

12 Registered trials

4 Recruiting

5 Completed trials

9 Sponsors

18 Countries

Phase III

Phase II

Phase I (FiH)

Phase III: 5 Phase II/III: 1 Phase II: 2 Phase I/II: 1 Phase I (FiH): 3

Oversight events:

19 temporary halts 1 urgent safety measure 2 corrective measures across 4 trials

View oversight register →

Indications tested

Epidermolysis bullosa 1 Type 1 diabetes mellitus 1 Multiple sclerosis 1 Methylmalonic aciduria 1 Glycogen storage disease type I 1

Sponsors using this IMP

Inmunotek S.L. 2 Itb-Med AB 2 Moderna Inc. 2 Celltrion Inc. 1 Centre Hospitalier Universitaire De Nantes 1 Charite Universitaetsmedizin Berlin KöR 1 Intellia Therapeutics Inc. 1 Region Stockholm – SLSO 1 Rheacell GmbH & Co. KG 1

All trials

12 total

A phase I/IIa, prospective, mono-center, double-blinded, randomized, controlled study to assess the safety and efficacy of applying PLX-PAD … Not authorised

2023-504212-15-00 Phase I/II 1 country Charite Universitaetsmedizin Berlin KöR
Rituximab as therapy for autoantibody mediated fibromyalgia (RAFT) - proof of concept Pending

2025-523465-21-00 Phase III 1 country Region Stockholm – SLSO
Phase III clinical trial of ABCB5+ MSCs for the treatment of EB Recruiting

2022-500266-10-00 Phase III 12 countries Rheacell GmbH & Co. KG
A prospective, randomized, double-blind, placebo-controlled, multicentre, dose-finding clinical trial with polymerised mannan-conjugated all… Recruiting

2025-524580-21-00 Phase II/III 1 country Inmunotek S.L.
Eight-Treg study: a phase I dose escalation trial of adoptive immunotherapy with autologous ex vivo expanded regulatory CD8+ T cells in livi… Recruiting

2024-513771-40-01 Phase I (FiH) 1 country Centre Hospitalier Universitaire De Nantes
Phase 1/2 study of mRNA-3705 in participants with Isolated MMA (Extension Study). Recruiting

2022-501997-20-00 Phase I (FiH) 3 countries Moderna Inc.
A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and S… Ended

2022-501622-37-00 Phase III 6 countries Celltrion Inc.
A Phase 3 Study of NTLA 2001 in participants with amyloidosis with cardiac muscle disease. Halted

2023-507220-23-00 Phase III 14 countries Intellia Therapeutics Inc.
A prospective, randomized, double-blind placebo-controlled multicentre trial with mannan-conjugated birch pollen allergoids administered sub… Ended

2024-515717-17-00 Phase III 1 country Inmunotek S.L.
A Phase 1/2, adaptive, open-label, single ascending dose to multiple ascending dose study to evaluate the safety, tolerability, pharmacokine… Ended

2022-502963-39-00 Phase I (FiH) 4 countries Moderna Therapeutics Inc.
A 12-month, randomized, single-blind, placebo-controlled exposure-response study of TCD601 (siplizumab) in new onset type 1 diabetes patient… Ended

2023-506837-31-00 Phase II 4 countries Itb-Med AB
A 12-Month Clinical Research Study to evaluate a new investigational medication (siplizumab) compared to another medication (anti thymocyte … Ended

2023-507895-36-00 Phase II 3 countries Itb-Med AB

Showing 1–12 of 12 trials

← All drugs A–Z